Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M108930200 on September 26, 2001

J. Biol. Chem., Vol. 276, Issue 49, 46326-46332, December 7, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/49/46326    most recent
M108930200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, X.-H.
Right arrow Articles by Youle, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, X.-H.
Right arrow Articles by Youle, R. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Inhibition of Axotomy-induced Neuronal Apoptosis by Extracellular Delivery of a Bcl-XL Fusion Protein*

Xiu-Huai LiuDagger , R. John Collier§, and Richard J. YouleDagger

From the Dagger  Biochemistry Section, Surgical Neurology Branch, NINDS, National Institutes of Health, Bethesda, Maryland 20892 and the § Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115

Received for publication, September 17, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bcl-2 and Bcl-XL prevent neuronal apoptosis during development, neurodegenerative disease, and trauma. To test a new anti-apoptosis strategy for neuroprotection, we engineered nontoxic components of anthrax toxin into a Bcl-XL delivery system. Delivery of Bcl-XL by this system prevented apoptosis of cultured rat cerebellar granule cells and macrophages, and the prevention depended on both the Bcl-XL and the anthrax toxin receptor binding/translocation moieties. Furthermore, neuronal death in vivo in a retinal ganglion cell model of axotomy-induced apoptosis was inhibited by administration of this fusion protein. Thus, Bcl-XL protein can be delivered into cells from the medium or interstitial space, offering a new way to block apoptosis upstream of many caspases and the mitochondria dysfunction phase of apoptosis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apoptosis plays an important role in neurodegeneration of cultured neurons (1), the neuronal death that occurs during normal development (2), post-traumatic injury (3-8), stroke (9, 10), and various neurodegenerative diseases (11-17).

Bcl-XL and Bcl-2 inhibit apoptosis of neurons and many other types of cells (18). Bcl-XL, an anti-apoptotic member of the Bcl-2 family (19), is globally expressed in the developing and mature mouse brain at levels higher than those of Bcl-2 (20). Bcl-XL knockout mice die in utero around embryonic day 13 and exhibit extensive apoptotic death of neurons in the brain, spinal cord, and dorsal root ganglia (21). In contrast, Bcl-2 is widely expressed in the developing nervous system, although, in the adult, expression persists at high levels only in the peripheral nervous system (22). Whereas the brains from embryonic homozygous Bcl-2 knockout mice appear to be grossly normal (23), the facial motoneurons and spinal cord sensory and sympathetic neurons exhibit degeneration postnatally (24). Thus, Bcl-2 appears to be necessary for postnatal peripheral neuronal survival, whereas Bcl-XL plays a more important role in preventing death in the central nervous system.

In vitro neuronal apoptosis induced by growth factor deprivation or cytotoxic drugs is delayed by overexpression of Bcl-2 (25). In Bcl-2 transgenic mice, Bcl-2 overexpression blocks naturally occurring neuronal death (26, 27) and reduces axotomy-induced (27-30), ischemia-induced (26), and chemically induced (31) neuronal death. Similarly, Bcl-XL overexpression inhibits axotomy-induced (32) and ischemia-induced apoptosis (32, 33) in transgenic mice.

Although Bcl-2 and Bcl-XL have potential to inhibit neurodegeneration, it is not now clinically practical to deliver genes to the brain. However, the transient delivery of anti-apoptotic proteins into neurons could help prevent neuronal death associated with traumatic injury and neurological diseases. Previously, Bcl-XL fused to the diphtheria toxin receptor binding domain, Bcl-XL-DTR, was found to prevent apoptosis in vitro induced by staurosporine, gamma -irradiation, and poliovirus (34). However, as diphtheria toxin receptors are present only on human and primate cells and the Bcl-XL-DTR protein does not inhibit apoptosis in rat and mouse cells (34), in vivo utility of the Bcl-XL fusion protein in rodent models could not be evaluated.

A nontoxic derivative of anthrax toxin has been shown to be a useful system to deliver peptides into the cytosolic compartment of mammalian cells (35). Anthrax toxin comprises three components: lethal factor (LF),1 edema factor (EF), and protective antigen (PA) (35). PA binds to an unidentified cell surface receptor existing on the cells of many species including rodents (35, 36) and, after being proteolytically activated, binds and transports LF or EF into cells (35). PA alone is not toxic (35). The first 254 residues of LF (LFn), which constitute the PA-binding domain, can mediate the delivery of heterologous peptides into the cytosol (35, 37-43). Initially, two splicing isoforms were discovered for human Bcl-X: Bcl-XL and Bcl-XS (19). Shortly thereafter, an alternatively spliced form of Bcl-XL lacking the C-terminal membrane anchor, Bcl-XDelta TM, was identified in mouse cells (44). Bcl-XL and Bcl-XDelta TM both inhibit apoptosis, whereas Bcl-XS promotes apoptosis. We fused human Bcl-XL and a truncated Bcl-XL lacking C-terminal membrane anchor (Delta Bcl-XL, similar to mouse Bcl-XDelta TM) to LFn and explored their effects on apoptosis in vitro and in vivo.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Construction of Prokaryotic Expression Plasmids-- The gene for LF from codons 34 to 288 (LFn) (45) was amplified by PCR from the template of pET15b/LFn (38). The genes of full-length human Bcl-XL and C-terminal truncated human Bcl-XL from codons 1 to 209 (Delta Bcl-XL) (19) were amplified by PCR, and the LFn gene was fused to the 5' end of the Bcl-XL gene or the Delta Bcl-XL gene by a second round of PCR. A stop codon was introduced immediately after the last codon of full-length Bcl-XL or codon 209 of Bcl-XL. The fused DNA fragments, LFn-Bcl-XL and LFn-Delta Bcl-XL, were cut with NdeI and XhoI and separately inserted into the prokaryotic expression vector pET15b cut with NdeI and XhoI (Fig. 1A). A histidine tag and a thrombin cleavage site were linked to the N terminus of LFn-Bcl-XL or LFn-Delta Bcl-XL. Similarly, the Delta Bcl-XL gene alone was also cloned into pET15b at the NdeI and XhoI sites. All the constructs were verified by DNA sequencing.

Construction of Eukaryotic Expression Plasmids, Transfection, Western Blotting, and Biologic Activity Assay-- The genes of LFn-Bcl-XL, LFn-Delta Bcl-XL (Fig. 1A), full-length Bcl-XL, and Delta Bcl-XL were separately cloned into the eukaryotic expression vector pcDNA3 and verified by DNA sequencing. COS-7 cells were transfected separately with the above four plasmids, and 12 h after transfection the cell lysates were loaded on SDS-PAGE, visualized by immunoblotting with anti-Bcl-XL monoclonal antibodies (2H12, Trevegen, Gaithersburg, MD), and developed by using enhanced chemiluminescence (Amersham Pharmacia Biotech) (Fig. 1B). As reported, COS-7 cells were co-transfected with one of the four above plasmids and the reporter plasmid, pEGFP-3C, which contains the green fluorescence protein (GFP) gene (46). The cells were treated with 0.8 µM staurosporine (STS) 12 h later. The dead and living cells expressing GFP were then counted at different times after STS treatment as reported previously (34, 46).

Protein Expression, Purification, SDS-PAGE, and Western Blotting-- The proteins LFn, LFn-Bcl-XL, LFn-Delta Bcl-XL, and Delta Bcl-XL were individually expressed in Escherichia coli BL21(DE3) (Novagen, Inc.) and purified with the His·Tag binding purification kit (Novagen, Inc.). The transformed BL21(DE3) were cultured at 37 °C in LB medium until the A600 reached 0.5-0.8, then treated with 1 mM isopropyl-1-thio-beta -D-galactopyranoside, and cultured for another 3 h. The cells expressing LFn-Bcl-XL were pelleted and lysed with a French press. The inclusion bodies were collected and dissolved in 6 M guanidine·HCl. His·Tag binding resin (Novagen) was used to purify LFn-Bcl-XL. LFn-Bcl-XL was refolded by dialysis against, or dilution into, 100 mM Tris·acetate (pH 8.0) plus 0.5 M arginine, concentrated with polyethylene glycol 15,000-20,000, and dialyzed against PBS. The cells expressing LFn, LFn-Delta Bcl-XL, and Delta Bcl-XL were pelleted and disrupted with a French press. The cytosol was loaded on the His·Tag binding column. The eluted proteins were dialyzed against PBS. PA was purified as reported (47). The proteins were run on SDS-PAGE gels and stained with Coomassie Blue or visualized by immunoblotting with anti-Bcl-XL monoclonal antibodies (2H12) and developed by using enhanced chemiluminescence (Fig. 2).

J744 Macrophage-like Cell Culture, Treatment, and Apoptosis Assay-- J744 macrophage-like cells at 105/ml were plated in 96-well plates in 100 µl of RPMI 1640 with 10% fetal calf serum/well and cultured overnight. The cells were treated with 0.1 µM STS along with different combinations of proteins or with PA or with PBS. The apoptotic and living cells were counted with Hoechst 33342 as reported elsewhere (34).

Cerebellar Granule Cell Culture, Treatment, and Viability Detection-- Cerebellar granule cells were prepared from 8-day-old Sprague-Dawley rat pups (15-19 g, Taconic Farms, Germantown, NY) as described by Levi et al. (48). The cells at 4 × 105/ml were plated in 96-well plates in 100 µl of basal Eagle's medium with 10% fetal calf serum, 2 mM glutamine, and 25 mM KCl per well. The cells were treated with 2.5 µg/ml Ara-C 24 h later to eliminate non-neuronal cells and cultured for 6 more days. The cerebellar granule cells were treated with PBS, 0.1 µM STS alone, 0.1 µM STS along with LFn-Delta Bcl-XL (47 µg/ml) plus PA (39 µg/ml), or with 0.1 µM STS along with different protein combinations. The apoptotic and living cells were counted with Hoechst 33342.

Western Blotting of Transfected Bad in J774 Cells Treated with the Fusion Protein-- J774 cells were transfected or co-transfected with the gene for GFP-bad, the genes for GFP-bad and Bcl-XL, or the genes for GFP-bad and Delta Bcl-XL. The GFP-bad gene was in pEGFP-3C, and Bcl-XL or Delta Bcl-XL was in pcDNA3. 12 h later, the cells transfected with GFP-bad were treated with proteins LFn-Delta Bcl-XL (60 µg/ml) plus PA (55 µg/ml). Five hours later, cell lysates were made and loaded onto SDS-PAGE, immunoblotted with antibody against phospho-Bad (Ser-136)2 or antibody against Bad (Cell Signaling Technology, Beverly, MA) and developed with enhanced chemiluminescence.

Optic Nerve Section and Intraocular Protein Injection-- The P0 pups of Fisher 344 rats were used for the present study. P0 is defined as the day of birth. The intracranial lesion of unilateral optic nerve was performed as reported (3). Briefly, a P0 pup was anesthetized by hypothermia. Under a dissecting microscope, an incision over the right eye was cut and a piece of bone flipped up. The right optic nerve was sectioned after suctioning the overlying tissue. The section site of the optic nerve is about 3 mm away from the eyeball. A piece of gelfoam was put in the hole, the bone was placed back, and the incision repaired with superglue.

Immediately after the operation, LFn-Delta Bcl-XL (0.65 µg) along with PA (0.35 µg) or PA alone (0.35 µg) or LFn-Delta Bcl-XL (0.65 µg) alone or PBS in a volume of 350 nl was injected through ora serrata into the posterior chamber of the eye by using a microinjector with a pulled micropipette. The pup was warmed up with a light lamp until the recovery, and then returned to the mother.

Histology-- 24 h after sectioning of the optic nerve, the right eyes were taken out under deep anesthesia with sodium pentobarbital, fixed in 4% paraformaldehyde for ~30 h, embedded in paraffin, and cut at 6 µm. The eyes taken from the normal pups in the same litters were processed in the same way and taken as controls. The sections were rehydrated, stained with 0.2% cresyl violet, dehydrated, and mounted with DPX mountant.

The pyknotic and living cells of the entire retinal ganglion cell layer of three sections per retina were counted by the use of a 40× objective. The pyknotic cells were identified as reported (3). The values were presented as the percentage of pyknotic cells versus total cells (see Fig. 6B).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Biological Activity of Transfected LFn-Bcl-XL and LFn-Delta Bcl-XL-- Bcl-XL was fused to the C terminus of LFn, leaving the Bcl-XL hydrophobic tail free in the resulting recombinant protein, LFn-Bcl-XL. An additional construct, lacking the Bcl-XL hydrophobic tail (LFn-Delta Bcl-XL), was made to examine whether this tail, which targets Bcl-XL to mitochondria, would help or hinder cell entry via the anthrax toxin (Fig. 1A). To compare the potential bioactivity of these two fusion proteins, the genes were transfected into mammalian cells prior to apoptosis induction by STS, a potent protein kinase inhibitor. LFn-Delta Bcl-XL inhibited apoptosis induced by staurosporine similarly to full-length LFn-Bcl-XL whereas native Bcl-XL or Delta Bcl-XL transfected into cells was slightly more active (Fig. 1C). The expression of the four transfected proteins was confirmed by Western blotting (Fig. 1B).


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 1.   Construction of LFn-Bcl-XL and LFn-Delta Bcl-XL. A, schematic diagram of the chimera LFn-Delta Bcl-XL. The fusion gene, LFn-Delta Bcl-XL, was inserted into either the E. coli vector, pET15b, yielding a histidine tag sequence at the N terminus of the LFn-Delta Bcl-XL gene or the mammalian expression vector, pcDNA3. B, the expression of Bcl-XL-derived proteins in COS-7 cells 12 h after transfection. Panel shows Western blotting with anti-Bcl-XL antibody. Lane a, Delta Bcl-XL; lane b, Bcl-XL; lane c, LFn-Delta Bcl-XL; lane d, LFn-Bcl-XL. C, transient co-transfection of Bcl-XL (triangle ), Delta Bcl-XL (black-down-triangle ), LFn-Bcl-XL (diamond ), or LFn-Delta Bcl-XL (open circle ) gene in pcDNA3 with pEGFP-C3 into COS-7 cells shows an inhibition of apoptosis induced by the addition of 0.8 µM STS compared with pcDNA3 vector and pEGFP-C3 co-transfected cells (). The apoptotic percentages are represented as the average ± S.D. of cell numbers from three independent wells in which five randomly chosen fields were counted. The data shown are representative of two independent experiments.

Characterization of Proteins Purified from E. coli by SDS-PAGE and Western Blotting-- To prepare these Bcl-XL fusion proteins for extracellular delivery, the proteins were expressed in E. coli and purified by affinity chromatography to near homogeneity, as shown by SDS-PAGE analysis (Fig. 2A). The control proteins LFn and Delta Bcl-XL were also expressed in E. coli and purified. The composition of LFn-Bcl-XL and LFn-Delta Bcl-XL was confirmed by Western blotting with anti-Bcl-XL antibody (Fig. 2B).


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 2.   Purification and characterization of the LFn-Bcl-XL, LFn-Delta Bcl-XL, Delta Bcl-XL, LFn and PA. A, SDS-PAGE. Lane a, Delta Bcl-XL; lane b, LFn-Bcl-XL; lane c, LFn-Delta Bcl-XL; lane d, LFn; lane e, PA. B, Western blotting with anti-Bcl-XL antibody. Lane a, Delta Bcl-XL; lane b, LFn-Bcl-XL; lane c, LFn-Delta Bcl-XL.

Biological Activity of Purified LFn-Bcl-XL and LFn-Delta Bcl-XL in Vitro-- The biological activity of the LFn-Bcl-XL and LFn-Delta Bcl-XL proteins was initially evaluated in tissue culture. LFn-Bcl-XL or LFn-Delta Bcl-XL and the anthrax toxin receptor binding and entry domain (PA) were added to the medium of J774 cells immediately after apoptosis was induced by STS. Cells treated with STS died by apoptosis over the following 36 h as shown in Fig. 3A. However, when the cells were treated with LFn-Bcl-XL plus PA or LFn-Delta Bcl-XL plus PA, most of the cell death was inhibited. Controls were performed to evaluate the requirements for apoptosis inhibition. Fig. 3B shows that J774 cells treated with LFn alone, Delta Bcl-XL alone, LFn-Delta Bcl-XL without PA, and PA without LFn-Delta Bcl-XL were not protected from apoptosis induced by STS, whereas LFn-Delta Bcl-XL with PA prevented more than half of the cell death (p < 0.001). This indicates that Delta Bcl-XL uses the anthrax toxin entry pathway to access the cell cytosol. Interestingly, LFn protein fused to Bcl-XL without the C-terminal hydrophobic tail appeared to prevent apoptosis to an extent similar to LFn protein fused to full-length Bcl-XL protein, indicating that the C terminus of Bcl-XL is not essential for the anti-apoptosis activity. This is consistent with certain previous studies in which C terminus-truncated Bcl-XL retained apoptosis inhibition activity (44, 46, 49) and with the results shown in Fig. 1C where transfection with Delta Bcl-XL prevents apoptosis. Similarly, Bcl-2 lacking the C-terminal hydrophobic tail retains anti-apoptosis activity (50-52), although truncating the C-terminal tail can impair the potency of apoptosis inhibition (52, 53).


View larger version (36K):
[in this window]
[in a new window]
  		Fig. 3.   Prevention of J774 cell apoptosis by Bcl-XL fusion proteins. A, the time course of apoptosis induced by STS in J774 cells with or without LFn-Bcl-XL protein plus PA or LFn-Delta Bcl-XL protein plus PA. J774 cells at 105/ml were treated with 0.1 µM STS alone, 0.1 µM STS along with LFn-Bcl-XL (28 µg/ml) plus PA (33 µg/ml), 0.1 µM STS along with LFn-Delta Bcl-XL (28 µg/ml) plus PA (33 µg/ml), or with PBS. Proteins and STS were added at the same time. The apoptotic percentages are represented as the average ± S.D. of cell numbers from three independent wells in which at least three randomly chosen fields were counted. The data shown are representative of three independent experiments. B, the effect of LFn-Delta Bcl-XL plus PA against J774 48 h after being treated with STS. J774 cells at 105/ml were treated with either PBS, 0.1 µM STS alone, 0.1 µM STS along with LFn-Delta Bcl-XL (28 µg/ml) plus PA (33 µg/ml), 0.1 µM STS along with LFn (28 µg/ml), 0.1 µM STS along with Delta Bcl-XL (28 µg/ml), 0.1 µM STS along with LFn-Delta Bcl-XL (28 µg/ml), 0.1 µM STS along with PA (33 µg/ml), or 0.1 µM STS along with LFn (28 µg/ml) plus PA (33 µg/ml). Proteins and STS were added at the same time. The apoptotic percentages are represented as the average ± S.D. of cell numbers from three independent wells in which at least three randomly chosen fields were counted. The asterisk indicates a statistically significant difference (p < 0.001) versus the STS-treated control derived from ANOVA analysis. The data shown are representative of four independent experiments. C, the effect of the pretreatment with LFn-Delta Bcl-XL plus PA against J774 cells prior to STS treatment. J774 cells at 105/ml were treated with PBS, 0.1 µM STS alone, or 0.1 µM STS along with LFn-Delta Bcl-XL (45 µg/ml) plus PA (42 µg/ml). Proteins were added either at various time points before, at the same time as, or after STS treatment. The apoptotic percentages are represented as the average ± S.D. of cell numbers from three independent wells in which at least three randomly chosen fields were counted. The data shown are representative of two independent experiments. D, the dose response of LFn-Delta Bcl-XL against J744 cells 30 h after being treated with STS. J774 cells at 105/ml were treated with different concentrations of LFn-Delta Bcl-XL along with PA kept constant at 33 µg/ml at the time of STS addition. The apoptotic percentages are represented as the average ± S.D. of cell numbers from three independent wells in which at least three randomly chosen fields were counted.

We determined the stability of LFn-Delta Bcl-XL apoptosis inhibition by adding it to the cell media at various times prior to STS treatment. The pretreatment of cells with LFn-Delta Bcl-XL up to 10 h before STS treatment is as effective as the treatment at the same time in preventing cells from apoptosis (Fig. 3C). Thus, the protein efficacy remains stable for at least 10 h. The protein was also partially effective at preventing cell death when added up to 1 h after apoptosis induction (Fig. 3C). The potency of LFn-Delta Bcl-XL was measured by examining its dose response in apoptosis protection. When less potent doses of STS are applied to cells that initiate only 15-20% apoptosis after 30 h, LFn-Delta Bcl-XL can block over 80% of the cell death (Fig. 3D). When the dose of PA is kept constant at 33 µg/ml, the dose of LFn-Delta Bcl-XL that is half-maximal at apoptosis prevention is less than 2 µg/ml or less than 40 nM (Fig. 3D). Thus, LFn-Delta Bcl-XL offers an extremely potent mechanism to prevent cell death.

As the C-terminal truncated LFn-Delta Bcl-XL is more soluble and easier to purify, we explored the potential of this protein in models of neuronal death in vitro and in vivo. We examined the effect of LFn-Delta Bcl-XL on apoptosis of primary rat cerebellar granule cells. The LFn-Delta Bcl-XL protein combined with PA inhibited STS-induced apoptosis of these neurons by about 30% after 45 h (p = 0.0017) (Fig. 4). However, Delta Bcl-XL alone, LFn-Delta Bcl-XL alone, PA alone, and PA plus LFn lacked significant bioactivity. Thus, in primary neuron cultures, as in the cultured macrophage cell line, Delta Bcl-XL protein can be delivered via the anthrax toxin entry pathway to prevent apoptosis.


View larger version (77K):
[in this window]
[in a new window]
  		Fig. 4.   The effect of LFn-Delta Bcl-XL on rat cerebellar granule cells 45 h after being treated with 0.1 µM STS. The cerebellar granule cells were treated with 0.1 µM STS alone, 0.1 µM STS along with LFn-Delta Bcl-XL (47 µg/ml) plus PA (39 µg/ml), 0.1 µM STS along with Delta Bcl-XL (49 µg/ml), 0.1 µM STS along with LFn-Delta Bcl-XL (47 µg/ml), 0.1 µM STS along with PA (39 µg/ml), or 0.1 µM STS along with PA (39 µg/ml) plus LFn (47 µg/ml). Proteins and STS were added at the same time. The apoptotic percentages are represented as the average ± S.D. of cell numbers from three independent wells in which at least three randomly chosen fields were counted. The asterisk indicates a statistically significant difference (p = 0.0017) versus the STS-treated control derived from ANOVA analysis. The data shown are representative of three independent experiments.

The Blockage of Bad Phosphorylation by LFn-Delta Bcl-XL-- We have recently found that overexpression of Bcl-XL or Delta Bcl-XL inhibits Bad phosphorylation at serine 136.2 We determined one cellular activity of LFn-Delta Bcl-XL by examining the effect of LFn-Delta Bcl-XL on this phosphorylation of Bad. As shown in Fig. 5, LFn-Delta Bcl-XL protein, like transfection with Bcl-XL and Delta Bcl-XL, effectively blocks Bad phosphorylation. This is consistent with a cytosolic delivery of Bcl-XL by LFn and demonstrates one similar cytosolic bioactivity between LFn-Delta Bcl-XL protein and endogenous overexpression of Bcl-XL or Bcl-XL lacking the C terminus.


View larger version (54K):
[in this window]
[in a new window]
  		Fig. 5.   The blockage of the phosphorylation of transfected Bad by either addition of LFn-Delta Bcl-XL plus PA or transfection with Bcl-XL or Delta Bcl-XL. Western blotting with an antibody against Bad (A) or an antibody against phospho-Bad (Ser-136) (B). a, GFP-bad-transfected; b, cotransfected with GFP-bad and Bcl-XL; c, cotransfected with GFP-bad and Delta Bcl-XL; d, GFP-bad-transfected and LFn-Delta Bcl-XL- plus PA-treated.

Biological Activity of Purified LFn-Delta Bcl-XL in Vivo-- This new strategy to block cell death was explored in an animal model of neuronal apoptosis. Neonatal rat retinal ganglion cells (RGCs) die by apoptosis within 24 h after optic nerve section (3). Retinal ganglion cells were axotomized, and within 5 min a protein mixture containing 0.35 µg of PA and 0.65 µg of LFn-Delta Bcl-XL was injected into the ipsilateral eye. Control mice were not axotomized, axotomized and injected with PBS, or axotomized and injected with LFn-Delta Bcl-XL alone or PA alone. Mice were sacrificed 24 h later, and the eyes were examined histologically. As seen in Fig. 6A, a great number of pyknotic cells, i.e. apoptotic cells (3), were found in the retinal ganglion cell layer 24 h after axotomy. However, when eyes were injected with LFn-Delta Bcl-XL and PA, much of the cell death was inhibited (Fig. 6A). LFn-Delta Bcl-XL alone or PA alone caused no obvious prevention of cell death. To quantitate the extent of cell death, the living and pyknotic cells in the entire retinal ganglion cell layers of three sections from one eye in each of 4-10 mice/group were counted. The results are shown in Fig. 6B. LFn-Delta Bcl-XL plus PA inhibited more than half of the cell death caused by neuronal axotomy in vivo (p < 0.001), whereas PA alone or LFn-Delta Bcl-XL alone had no significant effect.


View larger version (75K):
[in this window]
[in a new window]
  		Fig. 6.   Prevention of apoptosis by the fusion protein LFn-Delta Bcl-XL plus PA in neonatal rat retinal ganglion cells 24 h after optic nerve transection. A, photographs of retinal sections stained with cresyl violet. a, normal; b, axotomized and treated with PBS; c, axotomized and treated with LFn-Delta Bcl-XL plus PA; d, axotomized and treated with PA alone; e, axotomized and treated with LFn-Delta Bcl-XL alone. Arrows indicate apoptotic cells. B, quantitation of retinal ganglion cell protection by LFn-Delta Bcl-XL plus PA. Apoptotic and living cells in the entire retinal ganglion cell layer of three cresyl violet-stained sections/retina from 4-10 mice/group were counted, and the percentage of apoptotic cells versus total cells in retinal ganglion cells was plotted. Asterisk indicates a statistically significant difference (p < 0.001) versus axotomized and PBS-treated retinas derived from ANOVA analysis.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bcl-XL engineered to enter cells from the extracellular milieu inhibits neuron death in vitro and in vivo. Because neuron apoptosis occurs during many neurodegenerative diseases such as Alzheimer's disease (11-13), amyotrophic lateral sclerosis (17, 54), and Huntington's disease (15, 16), and exacerbates neuron loss from stroke (9, 10, 55) and traumatic injury to the optic nerve (3, 7, 8), spinal cord (4), and brain (5, 6), the Bcl-XL fusion protein has potential to promote the recovery of injured neurons and delay the progression of these diseases.

Bcl-2 (27-30) or Bcl-XL (32, 56) overexpression prevents neuron apoptosis in several axotomy models. For example, overexpression of a bcl-2 transgene increases RGC survival after axotomy in neonatal mice (27) and maintains the long-term survival (29) and normal electrophysiological response (57) of axotomized RGCs in adult mice. Bcl-2 overexpression also promotes the RGC axons to regrow (58). Some animal models of stroke show a benefit derived from Bcl-XL or Bcl-2 transgenic overexpression (26, 32, 33). Overexpression of Bcl-2 by viral gene transfer also reduces infarction after permanent and transient focal ischemia (59, 60). Several disease models also show benefit derived from Bcl-2 and Bcl-XL overexpression. Bcl-2 prolongs life in a mouse model of familial amyotrophic lateral sclerosis (54) and protects photoreceptor cells in different retinal degeneration models (61, 62). Thus, transgenic or viral-transduced overexpression of Bcl-2 or Bcl-XL appears to have a broad ability to prevent neuronal death.

Although delivery of the gene for Bcl-2 or Bcl-XL is not now clinically practical, methods of delivering protein to the central nervous system via direct infusion into the brain, cerebrospinal fluid, spinal cord, or peripheral nerves have been established in animals (63, 64) and man (65, 66). Thus, delivery of proteins that prevent apoptosis may inhibit certain neurodegenerative conditions. Here, we demonstrate that a single intravitreal administration of both LFn-Delta Bcl-XL and PA prevents 60% of the apoptosis induced by optic nerve section in the RGC layer of neonatal rats. Because only one concentration and single dose injection of both LFn-Delta Bcl-XL and PA have been tested in the present study, it is possible that a higher apoptosis-preventing effect could be achieved using increased protein dosage or increasing injection frequency.

It has been demonstrated that some neurotrophic factors promote the survival of neurons in vivo (67), but the clinical utility of neurotrophic factors thus far has not been dramatic. Nerve growth factor was confirmed to have therapeutic effects only on some sensory neuropathies (68, 69). Brain-derived neurotrophic factor in ALS patients had no effect on survival but exhibited a statistically significant benefit for those ALS patients with early respiratory impairment and altered bowel function (70). Ciliary neurotrophic factor exhibited mostly negative effects in ALS patients (71).

Direct delivery of LFn-Delta Bcl-XL may have an advantage over neurotrophic factors to increase neuron survival. In the nervous system, various neurotrophic factors protect different subsets of neurons only during certain developmental periods. For example, nerve growth factor maintains the survival of sympathetic neurons only during neonatal maturation. Because Bcl-XL is widely expressed in the central nervous system during development (20) and its overexpression protects against a broad range of neurotoxic insults (32, 33, 56), LFn-Delta Bcl-XL may have broad potential to prevent apoptosis of different types of neurons resulting from different insults at different stages of development. Here we show LFn-Delta Bcl-XL protects cerebellar granule cells, a macrophage-related cell line, and retinal ganglion cells from apoptosis. Previously, we found Bcl-XL-DTR prevents apoptosis caused by poliovirus, radiation, and STS (34).

The finding that the combination of LFn-Delta Bcl-XL and PA dramatically inhibits apoptosis in the J774 macrophage cell line also indicates that the fusion protein can be successfully delivered to non-neuronal cell lines to block cell death. Thus, a large number of uses outside the nervous system may also be considered as potential applications of Bcl-XL protein delivery.

    ACKNOWLEDGEMENTS

We thank Dr. Makoto Ichinose, Pat Johnson, and Joan Barrick for experimental help. We also thank Everett Robert for carefully reading the manuscript.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: NINDS, National Institutes of Health, Bldg. 10, Rm. 5D-37, MSC 1414, 10 Center Dr., Bethesda, MD 20892-1414. Tel.: 301-496-6628; Fax: 301-402-0380; E-mail: youle@helix.nih.gov.

Published, JBC Papers in Press, September 26, 2001, DOI 10.1074/jbc.M108930200

2 S. H. Yoon, K. Sanders, X.-H. Liu, Y.-T. Hsu, C. L. Smith, S. Frank, and R. J. Youle, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: LF, lethal factor; EF, edema factor; PA, protective antigen; STS, staurosporine; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; ALS, amyotrophic lateral sclerosis; GFP, green fluorescence protein; RGC, retinal ganglion cell; ANOVA, analysis of variance.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Martin, D. P., Schmidt, R. E., Di Stefano, P. S., Lowry, O. H., Carter, J. G., and Johnson, E. M. (1988) J. Cell Biol. 106, 829-844[Abstract/Free Full Text]
2. Wood, K. A., Dipasquale, B., and Youle, R. J. (1993) Neuron 11, 621-632[CrossRef][Medline] [Order article via Infotrieve]
3. Rabachi, S., Bonfanti, L., Liu, X. H., and Maffei, L. (1994) J. Neurosci. 14, 5292-5301[Abstract]
4. Crowe, M. J., Bresnahan, J. C., Shuman, S. L., Masters, J. N., and Beattie, M. S. (1997) Nat. Med. 3, 73-76[CrossRef][Medline] [Order article via Infotrieve]
5. Conti, A. C., Raghupathi, R., Trojanowski, J. Q., and McIntosh, T. K. (1998) J. Neurosci. 18, 5663-5672[Abstract/Free Full Text]
6. Harvey, A. R., Cui, Q., and Robertson, D. (1994) Eur. J. Neurosci. 6, 550-557[CrossRef][Medline] [Order article via Infotrieve]
7. Berkelaar, M., Clarke, D. B., Wang, Y. C., Bray, G. M., and Aguayo, A. J. (1994) J. Neurosci. 14, 4368-4374[Abstract]
8. Garcia-Valenzuela, E., Gorczyca, W., Darzynkiewicz, Z., and Sharma, S. C. (1994) J. Neurobiol. 25, 431-438[CrossRef][Medline] [Order article via Infotrieve]
9. Dirnagl, U., Iadecola, C., and Moskowitz, M. A. (1999) Trends Neurosci. 22, 391-397[CrossRef][Medline] [Order article via Infotrieve]
10. Choi, D. W. (1996) Curr. Opin. Neurobiol. 6, 667-672[CrossRef][Medline] [Order article via Infotrieve]
11. Lassmann, H., Bancher, C., Breitschopf, H., Wegiel, J., Bobinski, M., Jellinger, K., and Wisniewski, H. M. (1995) Acta Neuropathol. 89, 35-41[CrossRef][Medline] [Order article via Infotrieve]
12. Smale, G., Nichols, N. R., Brady, D. R., Finch, C. E., and Horton, W. E., Jr. (1995) Exp. Neurol. 55, 481-490
13. Gervais, F. G., Xu, D., Robertson, G. S., Vaillancourt, J. P., Zhu, Y., Huang, J., LeBlanc, A., Smith, D., Rigby, M., Shearman, M. S., Clarke, E. E., Zheng, H., Van Der Ploeg, L. H., Ruffolo, S. C., Thornberry, N. A., Xanthoudakis, S., Zamboni, R. J., Roy, S., and Nicholson, D. W. (1999) Cell 97, 395-406[CrossRef][Medline] [Order article via Infotrieve]
14. Sanchez, I., Xu, C. J., Juo, P., Kakizaka, A., Blenis, J., and Yuan, J. (1999) Neuron 22, 623-633[CrossRef][Medline] [Order article via Infotrieve]
15. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M. E. (1998) Cell 95, 55-66[CrossRef][Medline] [Order article via Infotrieve]
16. Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E., and Efstratiadis, A. (1995) Nat. Genet. 11, 155-163[CrossRef][Medline] [Order article via Infotrieve]
17. Friedlander, R. M., Brown, R. H., Gagliardini, V., Wang, J., and Yuan, J. (1997) Nature 388, 31[Medline] [Order article via Infotrieve]; Erratum (1998) Nature 392, 560
18. Adams, J. M., and Cory, S. (1998) Science 281, 1322-1326[Abstract/Free Full Text]
19. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., and Thompson, C. B. (1993) Cell 74, 597-608[CrossRef][Medline] [Order article via Infotrieve]
20. Gonzalez-Garcia, M., Perez-Ballestero, R., Ding, L., Duan, L., Boise, L. H., Thompson, C. B., and Nunez, G. (1994) Development 120, 3033-3042[Abstract]
21. Motoyama, N., Wang, F., Roth, K. A., Sawa, H., Nakayama, K., Nakayama, K., Negishi, I., Senju, S., Zhang, Q., Fujii, S., and Loh, D. Y. (1995) Science 267, 1506-1510[Abstract/Free Full Text]
22. Merry, D. E., Veis, D. J., Hickey, W. F., and Korsmeyer, S. J. (1994) Development 120, 301-311[Abstract]
23. Veis, D. J., Sorensen, C. M., Shutter, J. R., and Korsmeyer, S. J. (1993) Cell 75, 229-240[CrossRef][Medline] [Order article via Infotrieve]
24. Michaelidis, T. M., Sendtner, M., Cooper, J. D., Airaksinen, M. S., Holtmann, B., Meyer, M., and Thoenen, H. (1996) Neuron 17, 75-89[CrossRef][Medline] [Order article via Infotrieve]
25. Sastry, P. S., and Rao, K. S. (2000) J. Neurochem. 74, 1-20[CrossRef][Medline] [Order article via Infotrieve]
26. Martinou, J.-C., Dubois-Dauphin, M., Staple, J. K., Rodriguez, I., Frankowski, H., Missotten, M., Albertini, P., Talabot, D., Catsicas, S., Pietra, C., and Huarte, J. (1994) Neuron 13, 1017-1030[CrossRef][Medline] [Order article via Infotrieve]
27. Bonfanti, L., Strettoi, E., Chierzi, S., Cenni, M. C., Liu, X. H., Martinou, J.-C., Maffei, L., and Rabacchi, S. A. (1996) J. Neurosci. 16, 4186-4194[Abstract/Free Full Text]
28. Dubois-Dauphin, M., Frankowski, H., Tsujimoto, Y., Huarte, J., and Martinou, J. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3309-3313[Abstract/Free Full Text]
29. Cenni, M. C., Bonfanti, L., Martinou, J.-C., Ratto, G. M., Strettoi, E., and Maffei, L. (1996) Eur. J. Neurosci. 8, 1735-1745[CrossRef][Medline] [Order article via Infotrieve]
30. Farlie, P. G., Dringen, R., Rees, S. M., Kannourakis, G., and Bernard, O. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4397-4401[Abstract/Free Full Text]
31. Offen, D., Beart, P. M., Cheung, N. S., Pascoe, C. J., Hochman, A., Gorodin, S., Melamed, E., Bernard, R., and Bernard, O. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5789-5794[Abstract/Free Full Text]
32. Parsadanian, A. S., Cheng, Y., Keller-Peck, C. R., Holtzman, D. M., and Snider, W. D. (1998) Neuron 18, 1009-1019
33. Wiessner, C., Allegrini, P. R., Rupalla, K., Sauer, D., Oltersdorf, T., McGregor, A. L., Bischoff, S., Bottiger, B. W., and van der Putten, H. (1999) Neurosci. Lett. 268, 119-122[CrossRef][Medline] [Order article via Infotrieve]
34. Liu, X.-H., Castelli, J., and Youle, R. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9563-9567[Abstract/Free Full Text]
35. Leppla, S. H. (1995) in Handbook of Natural Toxins (Moss, J. , Iglewski, B. , Vaughan, M. , and Tu, A. T., eds), Vol. 8 , pp. 543-572, Marcel Dekker, Inc., New York
36. Friedlander, A. M. (1986) J. Biol. Chem. 261, 7123-7126[Abstract/Free Full Text]
37. Arora, N., Williamson, L. C., Leppla, S. H., and Halpern, J. L. (1994) J. Biol. Chem. 269, 26165-26171[Abstract/Free Full Text]
38. Milne, J. C., Blanke, S. R., Hanna, P. C., and Collier, R. J. (1995) Mol. Microbiol. 15, 661-666[CrossRef][Medline] [Order article via Infotrieve]
39. Goletz, T. J., Klimpel, K. R., Arora, N., Leppla, S. H., Keith, J. M., and Berzofsky, J. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12059-12064[Abstract/Free Full Text]
40. Ballard, J. D., Collier, R. J., and Starnbach, M. N. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12531-12534[Abstract/Free Full Text]
41. Ballard, J. D., Doling, A. M., Beauregard, K., Collier, R. J., and Starnbach, M. N. (1998) Infect. Immun. 66, 615-619[Abstract/Free Full Text]
42. Ballard, J. D., Collier, R. J., and Starnbach, M. N. (1998) Infect. Immun. 66, 4696-4699[Abstract/Free Full Text]
43. Doling, A. M., Ballard, J. D., Shen, H., Krishna, K. M., Ahmed, R., Collier, R. J., and Starnbach, M. N. (1999) Infect. Immun. 67, 3290-3296[Abstract/Free Full Text]
44. Fang, W., Rivard, J. J., Mueller, D. L., and Behrens, T. W. (1994) J. Immunol. 153, 4388-4398[Abstract]
45. Bragg, T. S., and Robertson, D. L. (1989) Gene (Amst.) 81, 45-54[CrossRef][Medline] [Order article via Infotrieve]
46. Wolter, K. G., Hsu, Y.-T., Smith, C. L., Nechushtan, A., Xi, X.-G., and Youle, R. J. (1997) J. Cell Biol. 139, 1281-1292[Abstract/Free Full Text]
47. Miller, C. J., Elliott, J. L., and Collier, R. J. (1999) Biochemistry 38, 10432-10441[CrossRef][Medline] [Order article via Infotrieve]
48. Levi, G., Aloisi, F., Ciotti, M. T., and Gallo, V. (1984) Brain Res. 290, 77-86[CrossRef][Medline] [Order article via Infotrieve]
49. Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S. L., Ng, S. L., and Fesik, S. W. (1996) Nature 381, 335-341[CrossRef][Medline] [Order article via Infotrieve]
50. Borner, C., Martinou, I., Mattmann, C., Irmler, M., Schaerer, E., Martinou, J.-C., and Tschopp, J. (1994) J. Cell Biol. 126, 1059-1068[Abstract/Free Full Text]
51. Vance, B. A., Zacharchuk, C. M., and Segal, D. M. (1996) J. Biol. Chem. 271, 30811-30815[Abstract/Free Full Text]
52. Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., and Korsmeyer, S. J. (1993) Cell 75, 241-251[CrossRef][Medline] [Order article via Infotrieve]
53. Nguyen, M., Branton, P. E., Walton, P. A., Oltvai, Z. N., Korsmeyer, S. J., and Shore, G. C. (1994) J. Biol. Chem. 269, 16521-16524[Abstract/Free Full Text]
54. Kostic, V., Jackson-Lewis, V., de Bilbao, F., Dubois-Dauphin, M., and Przedborski, S. (1997) Science 277, 559-562[Abstract/Free Full Text]
55. Rosenblum, W. I. (1999) Stroke 30, 1154-1156[Free Full Text]
56. Blomer, U., Kafri, T., Randolph-Moore, L., Verma, I. M., and Gage, F. H. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2603-2608[Abstract/Free Full Text]
57. Porciatti, V., Pizzorusso, T., Cenni, M. C., and Maffei, L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14955-14959[Abstract/Free Full Text]
58. Chen, D. F., Schneider, G. E., Martinou, J.-C., and Tonegawa, S. (1997) Nature 385, 434-439[CrossRef][Medline] [Order article via Infotrieve]
59. Linnik, M. D., Zahos, P., Geschwind, M. D., and Federoff, H. J. (1995) Stroke 26, 1670-1675[Abstract/Free Full Text]
60. Lawrence, M. S., Ho, D. Y., Sun, G. H., Steiberg, G. K., and Sapolsky, R. M. (1996) J. Neurosci. 16, 486-496[Abstract/Free Full Text]
61. Chen, J., Flannery, J. G., LaVail, M. M., Steinberg, R. H., Xu, J., and Simon, M. I. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7042-7047[Abstract/Free Full Text]
62. Nir, I., Kedzierski, W., Chen, J., and Travis, G. H. (2000) J. Neurosci. 20, 2150-2154[Abstract/Free Full Text]
63. Lonser, R. R., Gogate, N., Morrison, P. F., Wood, J. D., and Oldfield, E. H. (1998) J. Neurosurg. 89, 616-622[Medline] [Order article via Infotrieve]
64. Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., and Oldfield, E. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2076-2080[Abstract/Free Full Text]
65. Mufson, E. J., Kroin, J. S., Sendera, T. J., and Sobreviela, T. (1999) Prog. Neurobiol. 57, 451-484[CrossRef][Medline] [Order article via Infotrieve]
66. Laske, D. W., Youle, R. J., and Oldfield, E. H. (1997) Nat. Med. 3, 1362-1368[CrossRef][Medline] [Order article via Infotrieve]
67. Horner, P. J., and Gage, F. (2000) Nature 407, 963-970[CrossRef][Medline] [Order article via Infotrieve]
68. Apfel, S. C., Kessler, J. A., Adornato, B. T., Litchy, W. J., Sanders, C., and Rask, C. A. (1998) Neurology 51, 695-702[Abstract/Free Full Text]
69. McArthur, J. C., Yiannoutsos, C., Simpson, D. M., Adornato, B. T., Singer, E. J., Hollander, H., Marra, C., Rubin, M., Cohen, B. A., Tucker, T., Navia, B. A., Schifitto, G., Katzenstein, D., Rask, C., Zaborski, L., Smith, M. E., Shriver, S., Millar, L., Clifford, D. B., and Karalnik, I. (2000) Neurology 54, 1080-1088[Abstract/Free Full Text]; Erratum (2000) Neurology 55, 162
70. The BDNF Study Group. (1999) Neurology 52, 1427-1433[Abstract/Free Full Text]
71. Miller, R. G., Petajan, J. H., Bryan, W. W., Armon, C., Barohn, R. J., Goodpasture, J. C., Hoagland, R. J., Parry, G. J., Ross, M. A., and Stromatt, S. C. (1996) Ann. Neurol. 39, 256-260[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. Antignani and R. J. Youle
The Cytokine, Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF), Can Deliver Bcl-XL as an Extracellular Fusion Protein to Protect Cells from Apoptosis and Retain Differentiation Induction
J. Biol. Chem., April 13, 2007; 282(15): 11246 - 11254.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. Cao, W. Pei, H. Ge, Q. Liang, Y. Luo, F. R. Sharp, A. Lu, R. Ran, S. H. Graham, and J. Chen
In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis
J. Neurosci., July 1, 2002; 22(13): 5423 - 5431.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Ichinose, X.-H. Liu, N. Hagihara, and R. J. Youle
Extracellular Bad Fused to Toxin Transport Domains Induces Apoptosis
Cancer Res., March 1, 2002; 62(5): 1433 - 1438.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/49/46326    most recent
M108930200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, X.-H.
Right arrow Articles by Youle, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, X.-H.
Right arrow Articles by Youle, R. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement